InflaRx N.V Total Liabilities
InflaRx N.V total liabilities. Based on the latest financial reports, InflaRx N.V (IF0) has total liabilities worth €13.66 Million EUR (≈ $15.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of InflaRx N.V to evaluate the company's liquid asset resilience ratio.
Total Liabilities of InflaRx N.V (2016–2025)
Total liabilities of InflaRx N.V from 2016 to 2025. This chart illustrates how InflaRx N.V's total liabilities have evolved over time, based on quarterly financial data. Explore InflaRx N.V (IF0) investment intensity to see how much of total assets are deployed in long-term investments.
InflaRx N.V Competitors by Total Liabilities
The table below lists competitors of InflaRx N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reit Azorim HF Living Ltd
TA:AZRT
|
Israel | ILA2.36 Billion |
|
Argent
JSE:ART
|
South Africa | ZAC836.08 Million |
|
Shanghai Waigaoqiao Free Trade Zone Group Co Ltd B
SHG:900912
|
China | $30.68 Billion |
|
UBM Development AG
VI:UBS
|
Austria | €740.65 Million |
|
CASH CONVERTERS INTL
F:UKC
|
Germany | €257.79 Million |
|
Norstar
TA:NSTR
|
Israel | ILA24.61 Billion |
|
Grammer AG
XETRA:GMM
|
Germany | €1.43 Billion |
|
Lake Superior Acquisition Corp. Class A Ordinary Shares
NASDAQ:LKSP
|
USA | $4.92 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down InflaRx N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see InflaRx N.V balance sheet assets.
Liquidity & Leverage Metrics
InflaRx N.V Total Liabilities Ratios Explained
InflaRx N.V total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InflaRx N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InflaRx N.V (2016–2025)
The table below shows the annual total liabilities of InflaRx N.V from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €13.66 Million ≈ $15.97 Million |
-6.46% |
| 2024-12-31 | €14.60 Million ≈ $17.07 Million |
-17.16% |
| 2023-12-31 | €17.63 Million ≈ $20.61 Million |
+25.46% |
| 2022-12-31 | €14.05 Million ≈ $16.43 Million |
-29.25% |
| 2021-12-31 | €19.86 Million ≈ $23.22 Million |
+91.83% |
| 2020-12-31 | €10.35 Million ≈ $12.10 Million |
-28.26% |
| 2019-12-31 | €14.43 Million ≈ $16.87 Million |
+84.45% |
| 2018-12-31 | €7.82 Million ≈ $9.15 Million |
+63.52% |
| 2017-12-31 | €4.78 Million ≈ $5.59 Million |
-91.33% |
| 2016-12-31 | €55.21 Million ≈ $64.54 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more